Literature DB >> 9675454

Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients.

K K Miller1, P A Daly, D Sentochnik, J Doweiko, M Samore, N O Basgoz, S K Grinspoon.   

Abstract

To our knowledge, an association between human immunodeficiency virus infection and pseudo-Cushing's syndrome has not previously been described. We describe four HIV-infected patients with pseudo-Cushing's syndrome, characterized by striking dorsocervical and submandibular fat accumulation and central obesity. In each case, cortisol levels were either normal or suppressed adequately with administration of dexamethasone, excluding the diagnosis of true Cushing's syndrome. Immune function and weight improved significantly preceding the development of pseudo-Cushing's syndrome. Three of the four patients were taking a common protease inhibitor at the onset of symptoms, and the fourth reported the exacerbation of his symptoms with the addition of a protease inhibitor. The observed characteristic pattern of fat deposition may be attributable to a specific effect of new antiretroviral therapies or may relate to recovery independent of medication usage. Distinguishing between pseudo-Cushing's syndrome and true Cushing's syndrome is critical for preventing the unnecessary and potentially harmful treatment of such patients. Further research into the mechanisms of this novel phenomenon is needed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675454     DOI: 10.1086/514638

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Authors:  O Zachrisson; P Colque-Navarro; C G Gottfries; B Regland; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

2.  Metabolically deficient methicillin-resistant Staphylococcus aureus as cause of chronic post-thoracotomy sternal wound infection.

Authors:  A Roggenkamp; A Haas; W Eder; E Kreuzer; H Hoffmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

3.  Fat distribution in men with HIV infection.

Authors:  Peter Bacchetti; Barbara Gripshover; Carl Grunfeld; Steven Heymsfield; Heather McCreath; Dennis Osmond; Michael Saag; Rebecca Scherzer; Michael Shlipak; Phyllis Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

4.  Fat distribution in women with HIV infection.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

Review 5.  Pathogenesis and treatment of HIV lipohypertrophy.

Authors:  Vivien L Leung; Marshall J Glesby
Journal:  Curr Opin Infect Dis       Date:  2011-02       Impact factor: 4.915

6.  Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

Authors:  Sotirios Tsiodras; Christos Mantzoros
Journal:  Am J Infect Dis       Date:  2006

Review 7.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

8.  Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study.

Authors:  Carl Grunfeld; David Rimland; Cynthia L Gibert; William G Powderly; Stephen Sidney; Michael G Shlipak; Peter Bacchetti; Rebecca Scherzer; Steven Haffner; Steven B Heymsfield
Journal:  J Acquir Immune Defic Syndr       Date:  2007-11-01       Impact factor: 3.731

9.  In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.

Authors:  J Sutinen; K Kannisto; E Korsheninnikova; T Nyman; E Ehrenborg; R Andrew; D J Wake; A Hamsten; B R Walker; H Yki-Järvinen
Journal:  Diabetologia       Date:  2004-09-29       Impact factor: 10.122

Review 10.  Metabolic complications associated with HIV protease inhibitor therapy.

Authors:  David Nolan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.